10-Q Filing

Astrana Health, Inc. CIK: 1083446 Q2 2016

Filing Information

Form Type	10-Q
Accession Number	`0001144204-16-134062`
Period End Date	20160930
Filing Date	20161114
Fiscal Year	2016
Fiscal Period	Q2
XBRL Instance	ameh-20160930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 68 Cash Flow Statement 76

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.92M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$601.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $671,000 and $601,000 at September 30, 2016 and March 31, 2016, respectively	`AccountsReceivableNetCurrent`	$4.58M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $671,000 and $601,000 at September 30, 2016 and March 31, 2016, respectively	`AccountsReceivableNetCurrent`	$3.39M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$671.00K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$290.94K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$581.21K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$20.05K	USD	Point-in-time
Due from affiliates	`DueFromAffiliateCurrent`	$20.50K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$293.83K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$430.28K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.56M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.11M	USD	Point-in-time
Deferred financing costs	`DeferredFinanceCostsNoncurrentNet`	$37.93K	USD	Point-in-time
Deferred financing costs	`DeferredFinanceCostsNoncurrentNet`	-	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.25M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.30M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$530.00K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	5.88M	shares	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$530.00K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.03M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$2.16M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.03M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$2.35M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	5.88M	shares	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$216.44K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$221.98K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$14.95M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$19.57M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.57M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.54M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$2.67M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$2.07M	USD	Point-in-time
Lines of credit	`NotesAndLinesOfCreditPayableCurrent`	$188.76K	USD	Point-in-time
Lines of credit	`NotesAndLinesOfCreditPayableCurrent`	$201.26K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.43M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$6.82M	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$2.81M	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$1.48M	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$819.38K	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$728.88K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$43.48K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$43.48K	USD	Point-in-time
Total liabilities	`Liabilities`	$11.02M	USD	Point-in-time
Total liabilities	`Liabilities`	$9.16M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B); 1,111,111 issued and outstanding Liquidation preference of $9,999,999	`TemporaryEquityCarryingAmountAttributableToParent`	$7.08M	USD	Point-in-time
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B); 1,111,111 issued and outstanding Liquidation preference of $9,999,999	`TemporaryEquityCarryingAmountAttributableToParent`	$7.08M	USD	Point-in-time
Common Stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively	`CommonStockValue`	$5.88K	USD	Point-in-time
Common Stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding as of September 30, 2016 and March 31, 2016, respectively	`CommonStockValue`	$6.03K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapital`	$24.19M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapital`	$23.52M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-31.36M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-28.68M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-3.28M	USD	Point-in-time
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-1.27M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$2.00M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$2.74M	USD	Point-in-time
Total stockholders' (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-1.28M	USD	Point-in-time
Total stockholders' (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.47M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$14.95M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	`LiabilitiesAndStockholdersEquity`	$19.57M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`Revenues`	$21.57M	USD	2 Qtrs
Net revenues	`Revenues`	$11.37M	USD	1 Quarter
Net revenues	`Revenues`	$14.62M	USD	1 Quarter
Net revenues	`Revenues`	$26.99M	USD	2 Qtrs
Cost of services	`CostOfServices`	$22.30M	USD	2 Qtrs
Cost of services	`CostOfServices`	$8.26M	USD	1 Quarter
Cost of services	`CostOfServices`	$12.17M	USD	1 Quarter
Cost of services	`CostOfServices`	$15.83M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.29M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$4.46M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.44M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$7.68M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$77.68K	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$335.21K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$141.44K	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$170.56K	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$11.78M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$16.80M	USD	1 Quarter
Total costs and expenses	`OperatingExpenses`	$23.65M	USD	2 Qtrs
Total costs and expenses	`OperatingExpenses`	$30.93M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-3.94M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-412.91K	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-2.17M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-2.08M	USD	2 Qtrs
Interest expense	`InterestExpense`	$429.22K	USD	2 Qtrs
Interest expense	`InterestExpense`	$3.05K	USD	1 Quarter
Interest expense	`InterestExpense`	$68.82K	USD	1 Quarter
Interest expense	`InterestExpense`	$5.71K	USD	2 Qtrs
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$1.33M	USD	2 Qtrs
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$-116.87K	USD	2 Qtrs
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$511.11K	USD	1 Quarter
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$96.85K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$5.91K	USD	2 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$-95.09K	USD	1 Quarter
Other income (expense)	`OtherNonoperatingIncomeExpense`	$12.53K	USD	2 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$10.56K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-67.06K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$518.62K	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-540.17K	USD	2 Qtrs
Total other income (expense), net	`NonoperatingIncomeExpense`	$1.34M	USD	2 Qtrs
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.66M	USD	1 Quarter
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-2.60M	USD	2 Qtrs
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-2.62M	USD	2 Qtrs
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-479.96K	USD	1 Quarter
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-185.04K	USD	1 Quarter
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-226.59K	USD	2 Qtrs
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-93.45K	USD	2 Qtrs
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-186.14K	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.47M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.37M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-2.52M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-293.83K	USD	1 Quarter
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$303.53K	USD	2 Qtrs
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$489.40K	USD	2 Qtrs
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$237.54K	USD	1 Quarter
Net (income) loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-112.34K	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-3.01M	USD	2 Qtrs
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-2.67M	USD	2 Qtrs
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-531.37K	USD	1 Quarter
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-1.36M	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.11	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.45	USD	2 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.23	USD	1 Quarter
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.62	USD	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	4.86M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.97M	shares	2 Qtrs
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.02M	shares	1 Quarter
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	4.86M	shares	1 Quarter

Cash Flow Statement 76 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-1.47M	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.37M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-2.52M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-293.83K	USD	1 Quarter
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	-	USD	2 Qtrs
Provision for doubtful accounts, net of recoveries	`ProvisionForDoubtfulAccounts`	$69.63K	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-6.18K	USD	2 Qtrs
Loss on disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	-	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$77.68K	USD	1 Quarter
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$335.21K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$141.44K	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$170.56K	USD	1 Quarter
Deferred income tax	`DeferredIncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Deferred income tax	`DeferredIncomeTaxExpenseBenefit`	$6.13K	USD	2 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$246.04K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$152.73K	USD	2 Qtrs
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$68.89K	USD	1 Quarter
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$493.76K	USD	2 Qtrs
Amortization of deferred financing costs	`AdjustmentForAmortization`	$37.93K	USD	2 Qtrs
Amortization of deferred financing costs	`AdjustmentForAmortization`	$46.74K	USD	2 Qtrs
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	-	USD	2 Qtrs
Amortization of debt discount	`AmortizationOfDebtDiscountPremium`	$-47.88K	USD	2 Qtrs
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$1.33M	USD	2 Qtrs
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$-116.87K	USD	2 Qtrs
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$511.11K	USD	1 Quarter
Change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$96.85K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$214.13K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.25M	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-290.27K	USD	2 Qtrs
Other receivables	`IncreaseDecreaseInOtherReceivables`	$80.78K	USD	2 Qtrs
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-453.00	USD	2 Qtrs
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-16.34K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$131.09K	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$136.45K	USD	2 Qtrs
Deferred financing costs	`IncreaseDecreaseInDeferredCharges`	$-513.65K	USD	2 Qtrs
Deferred financing costs	`IncreaseDecreaseInDeferredCharges`	-	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$5.54K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-6.57K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.59M	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-27.60K	USD	2 Qtrs
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$90.50K	USD	2 Qtrs
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	-	USD	2 Qtrs
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$76.64K	USD	2 Qtrs
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-601.32K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-328.83K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-4.41M	USD	2 Qtrs
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$205.78K	USD	2 Qtrs
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$42.57K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-42.57K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-205.78K	USD	2 Qtrs
Proceeds from Lines of Credit	`ProceedsFromLinesOfCredit`	-	USD	2 Qtrs
Proceeds from Lines of Credit	`ProceedsFromLinesOfCredit`	$75.00K	USD	2 Qtrs
Principal payments on note payable	`PrincipalPaymentsOnTermNotePayable`	$122.50K	USD	2 Qtrs
Principal payments on note payable	`PrincipalPaymentsOnTermNotePayable`	-	USD	2 Qtrs
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$595.42K	USD	2 Qtrs
Distributions to non-controlling interest shareholder	`PaymentsToMinorityShareholders`	$1.05M	USD	2 Qtrs
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	$172.00K	USD	2 Qtrs
Proceeds from the exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	2 Qtrs
Principal payments on lines of credit	`RepaymentsOfNotesPayable`	-	USD	2 Qtrs
Principal payments on lines of credit	`RepaymentsOfNotesPayable`	$62.50K	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-717.92K	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$-865.50K	USD	2 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-5.48M	USD	2 Qtrs
Net decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.09M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.92M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.92M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.79M	USD	Point-in-time
Interest paid	`InterestPaid`	$380.75K	USD	2 Qtrs
Interest paid	`InterestPaid`	$10.20K	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaid`	$32.20K	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaid`	$16.40K	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.